<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2616">
  <stage>Registered</stage>
  <submitdate>16/12/2009</submitdate>
  <approvaldate>16/12/2009</approvaldate>
  <nctid>NCT01034410</nctid>
  <trial_identification>
    <studytitle>A Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia</studytitle>
    <scientifictitle>An Open-label Randomized Controlled Phase II Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>AS1411-C-203</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Acute Myeloid Leukemia</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Acute leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Chronic leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Children's - Leukaemia &amp; Lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - AS1411
Treatment: drugs - Cytarabine

Active Comparator: Control - cytarabine 2g/m2 bid Days 4-7

Experimental: AS1411-40 - AS1411 40mg/kg/day d1-7 plus cytarabine 2g/m2 bid days 4-7

Experimental: AS1411-80 - AS1411 80mg/kg/day d1-7, cytarabine 2g/m2 bid days 4- 7/ bid d4-7


Treatment: drugs: AS1411
AS1411 40mg/kg/day or AS1411 80mg/kg/day

Treatment: drugs: Cytarabine
Cytarabine 2g/m2 bid Days 4-7

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To compare the response rate (CR + CRi) of AS1411 at 40 and 80mg/kg/day in combination with cytarabine therapy with the response rate (CR + CRi) of cytarabine therapy alone</outcome>
      <timepoint>Dec 2011</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To compare duration of remission, disease free survival and overall survival of AS1411 at 40 or 80mg/kg/day in combination with cytarabine therapy with that of cytarabine alone.</outcome>
      <timepoint>Dec 2011</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To compare the time to hematological recovery of AS1411 at 40 or 80mg/kg/day in combination with cytarabine therapy with that of cytarabine alone.</outcome>
      <timepoint>Dec 2011</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To compare the safety of AS1411 at 40 or 80mg/kg/day in combination with cytarabine therapy with that of cytarabine alone.</outcome>
      <timepoint>Dec 2011</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate and compare a range of PD markers in patients administered AS1411 in combination with cytarabine therapy with the same PD markers in patients administered cytarabine therapy alone.</outcome>
      <timepoint>Dec 2011</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To further define the PK of AS1411</outcome>
      <timepoint>Dec 2011</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Diagnosis of AML as defined by the World Health Organization (WHO) classification
             (Vardiman 2009)

          -  Primary refractory AML (defined as a failure to achieve a CR or CRi after therapy with
             curative intent) or AML in first relapse

          -  ECOG Performance status 0, 1 or 2

          -  Age &gt; 18 and &lt; 70 years

          -  For patients presenting with primary refractory AML, &gt; 20% blasts on baseline bone
             marrow assessment

          -  For patients presenting with relapsed AML, &gt; 5% blasts on baseline bone marrow
             assessment</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  An initial diagnosis of acute promyelocytic leukemia (as defined by
             French-American-British criteria (Bennett 1976))

          -  Secondary AML, defined as AML evolving from antecedent hematological disorder or prior
             exposure to leukemogenic therapy or agent

          -  Clinically active CNS leukemia

          -  Previously received a total cumulative dose of cytarabine &gt; 6g/m2 in the last 6 months

          -  Previously received &gt; 1 induction regimen (Defined as 1 or 2 cycles of a drug or a
             drug combination administered as remission induction therapy)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>90</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/01/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,SA,VIC,WA</recruitmentstate>
    <hospital>Royal North Shore Hospital - St Leonards</hospital>
    <hospital>Westmead Hospital - Westmead</hospital>
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>The Alfred Hospital - Melbourne</hospital>
    <hospital>Royal Perth Hospital - Perth</hospital>
    <postcode>2065 - St Leonards</postcode>
    <postcode>2145 - Westmead</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>3004 - Melbourne</postcode>
    <postcode>6000 - Perth</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Changhua Country</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taichung City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Antisoma Research</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is an open label randomized controlled phase II study of AS1411 combined with Cytarabine
      in the treatment of patients with primary refractory or relapsed acute myeloid leukemia.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01034410</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Rob Stuart, MD</name>
      <address>Medical University of South Carolina</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>